BioPortfolio Blog about Biotechnology, Pharmaceutical and Healthcare

06:18 EST 28th November 2015 | BioPortfolio

Updates and info from the contributors bringing you

Showing News Articles 1–5 of 323

Monday 16th June 2014

Medtronic in $43bn acquisition of Covidien - comment from Healthcare Analyst at The Economist Intelligence Unit

"Given the hostile reaction on both sides of the Atlantic to Pfizer's proposed tax inversion deal with AstraZeneca, it is no wonder that Medtronic is playing down the tax benefits of its deal with Covidien. Instead it is predicting innovation benefits, as well as considerable cost-savings from combining the two companies' back-office, supply chain and manufacturing functions. It als...

Wednesday 26th March 2014

Comments following NICE's announcement on Sanofi's Zaltrap Bowel Cancer drug

Following NICE's announcement on Sanofi's Zaltrap Bowel Cancer drug - Steve Oldfield, Sanofi’s Managing Director UK and Ireland commented: “We are extremely disappointed NICE has not approved aflibercept, particularly given that based on the same basic evidence, the Scottish Medicin...

Monday 17th March 2014

World CDx Frankfurt 2014

World CDx Frankfurt is the premier networking, interactive and solution-led conference to overcome clinical biomarker, commercialisation, regulatory and reimbursement hurdles facing successful companion diagnostic development. Furthermore, the genomic revolution and advances in next generation sequencing are providing Rx/Dx partnerships with new toolkits to streamline co-development and bring pr...

Monday 10th March 2014

Most Alzheimer's drugs available treat symptoms not cause so new test is important breakthrough says Healthcare Analyst at The Economist Intelligence Unit

“This is the first time that researchers have developed a blood test that can predict who will go on to develop dementia or Alzheimer's, and it represents an important breakthrough. Research suggests that Alzheimer's begins developing years before symptoms such as short-term memory loss start, but scientists have struggled to understand the causes or progression of the disease. A g...

Thursday 27th February 2014

Alzheimer's market to increase from $3.6 billion in 2012 to $3.8 billion in 2019

As a result of Phase III therapy LMTX potentially entering the Alzheimer’s Disease (AD) industry in the near future, the AD market will increase slightly from $3.6 billion in 2012 to $3.8 billion in 2019. The current AD market with the available products is in serious decline. However, this could be offset by LMTX should it be approved, which is far from certain in a market characterized b...